Hasselbalch, Hans Carl http://orcid.org/0000-0003-3936-8032
Holmström, Morten Orebo
Article History
Received: 10 July 2018
Accepted: 6 August 2018
First Online: 10 September 2018
Compliance with ethical standards
:
: No authors have conflicts of interest to disclose. However, it should be noted that Morten Orebo Holmström and Hans Carl Hasselbalch together with Mads Hald Andersen have filed a patent regarding the <i>CALR</i> exon 9 mutations and <i>JAK2</i>V61F-mutation as a target for cancer immune therapy. The patent has been transferred to University Hospital Zealand, Zealand Region, and Copenhagen University Hospital at Herlev, Capital Region, according to Danish Law concerning inventions made at public research institutions.